KR100552634B1 - 돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 - Google Patents
돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 Download PDFInfo
- Publication number
- KR100552634B1 KR100552634B1 KR1020030077256A KR20030077256A KR100552634B1 KR 100552634 B1 KR100552634 B1 KR 100552634B1 KR 1020030077256 A KR1020030077256 A KR 1020030077256A KR 20030077256 A KR20030077256 A KR 20030077256A KR 100552634 B1 KR100552634 B1 KR 100552634B1
- Authority
- KR
- South Korea
- Prior art keywords
- promoter
- vector
- protein
- present
- pup2
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 122
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 80
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- 102000012349 Uroplakins Human genes 0.000 title 1
- 108010061861 Uroplakins Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 claims abstract description 74
- 239000013604 expression vector Substances 0.000 claims abstract description 60
- 241001465754 Metazoa Species 0.000 claims abstract description 36
- 210000002700 urine Anatomy 0.000 claims abstract description 19
- 230000009261 transgenic effect Effects 0.000 claims abstract description 17
- 241000282887 Suidae Species 0.000 claims abstract description 8
- 101150062179 II gene Proteins 0.000 claims abstract description 7
- 102000003951 Erythropoietin Human genes 0.000 claims description 44
- 108090000394 Erythropoietin Proteins 0.000 claims description 44
- 229940105423 erythropoietin Drugs 0.000 claims description 36
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 36
- 239000012212 insulator Substances 0.000 claims description 16
- 229930193140 Neomycin Natural products 0.000 claims description 14
- 229960004927 neomycin Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 101150002621 EPO gene Proteins 0.000 claims description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 8
- 241000282898 Sus scrofa Species 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 6
- 102000044890 human EPO Human genes 0.000 claims description 6
- 241000283923 Marmota monax Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 230000001124 posttranscriptional effect Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 55
- 230000001766 physiological effect Effects 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 44
- 239000000243 solution Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 210000003932 urinary bladder Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 15
- 108010065940 Uroplakin II Proteins 0.000 description 14
- 102000013532 Uroplakin II Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 210000003101 oviduct Anatomy 0.000 description 9
- 102100038851 Uroplakin-2 Human genes 0.000 description 8
- 101710173761 Uroplakin-2 Proteins 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000003443 bladder cell Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 210000005068 bladder tissue Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000001177 vas deferen Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100021879 Adenylyl cyclase-associated protein 2 Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000897856 Homo sapiens Adenylyl cyclase-associated protein 2 Proteins 0.000 description 1
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 1
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 description 1
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- XMWGSPLTTNCSMB-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;chloride Chemical compound [Na+].[Cl-].OC(=O)CC(O)(C(O)=O)CC(O)=O XMWGSPLTTNCSMB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
배양시간 | DMEM/F12(%) | FBS | FBS+시판 EPO | FBS+본 발명의 EPO |
24 | 38.5 ±6.8 | 54.9 ±4.3 | 58.2 ±6.6 | 72.1 ±4.7 |
48 | 21.6 ±7.4 | 39.9 ±2.9 | 50.0 ±2.4 | 60.4 ±7.5 |
72 | 10.0 ±4.6 | 20.8 ±11.7 | 39.6 ±3.8 | 53.9 ±4.0 |
Claims (12)
- 서열번호 1의 구조를 갖는 돼지의 유로플라킨 Ⅱ 유전자의 프로모터
- 삭제
- 제 1항의 프로모터 염기서열 및 그 3' 쪽으로 목적단백질을 암호화하는 염기서열을 포함함을 특징으로 하는 발현 벡터
- 제 3항에 있어서, 목적단백질은 인간 EPO(erythropoietin)임을 특징으로 하는 발현 벡터
- 제 4항에 있어서, 기탁번호 KCTC 10352BP로 기탁된 발현 벡터 pUP2/hEPO
- 제 4항에 있어서, 선택적 표지 유전자(selective marker)로 서열번호 5의 네오마이신 저항성 유전자(neomycin-resistant gene)를 포함하며, UP2 프로모터의 5' 쪽에 서열번호 6의 인슐레이터(insulator)를 포함함을 특징으로 하는 I/pUP2/hEPO 벡터
- 제 4항에 있어서, 선택적 표지 유전자로 서열번호 5의 네오마이신 저항성 유전자를 포함하며, EPO 유전자의 3' 쪽에 서열번호 7의 WPRE(woodchuck hepatitus virus posttranscriptional regulatory element)를 포함함을 특징으로 하는 pUP2/hEPO(WPRE) 벡터
- 제 4항에 있어서, 선택적 표지 유전자로 서열번호 5의 네오마이신 저항성 유전자를 포함하며, UP2 프로모터의 5' 쪽에 서열번호 6의 인슐레이터를 포함하고, EPO 유전자의 3' 쪽에 서열번호 7의 WPRE를 포함함을 특징으로 하는 I/pUP2/hEPO(WPRE) 벡터
- 제 3항 내지 제 8항 중 어느 한 항의 발현 벡터를 도입시킨 동물 수정란
- 제 9항의 수정란을 이식시켜 얻음을 특징으로 하는 형질전환동물
- 제 10항에 있어서, 돼지, 생쥐, 소, 닭, 양 또는 염소 중 선택된 하나임을 특징으로 하는 형질전환동물
- 제 3항 내지 제 8항 중 어느 한 항의 발현 벡터를 도입시킨 동물 수정란을 대리모 동물에 이식하고, 상기 대리모 동물로부터 형질전환동물을 얻고, 상기 형질전환동물의 소변으로부터 유용단백질을 분리ㆍ정제하는 단계로 이루어짐을 특징으로 하는 유용단백질의 제조 방법
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2003/002339 WO2004042062A1 (en) | 2002-11-04 | 2003-11-04 | Porcine uroplakin ii promoter and the production method of useful proteins using said promoter |
US10/532,580 US7416886B2 (en) | 2002-11-04 | 2003-11-04 | Porcine uroplakin II promoter and the production method of useful proteins using said promoter |
DE60318882T DE60318882D1 (de) | 2002-11-04 | 2003-11-04 | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors |
AU2003277694A AU2003277694A1 (en) | 2002-11-04 | 2003-11-04 | Porcine uroplakin ii promoter and the production method of useful proteins using said promoter |
CN200380101482XA CN1705743B (zh) | 2002-11-04 | 2003-11-04 | 猪uroplakinⅡ启动子和使用所述启动子生产有用蛋白质的方法 |
AT03810691T ATE384790T1 (de) | 2002-11-04 | 2003-11-04 | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors |
JP2004549679A JP4354404B2 (ja) | 2002-11-04 | 2003-11-04 | ブタウロプラキンiiプロモーター及び該プロモーターを利用した有用タンパク質の生産方法 |
EP03810691A EP1558735B1 (en) | 2002-11-04 | 2003-11-04 | Porcine uroplakin ii promoter and the production method of useful proteins using said promoter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20020067856 | 2002-11-04 | ||
KR1020020067856 | 2002-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040039168A KR20040039168A (ko) | 2004-05-10 |
KR100552634B1 true KR100552634B1 (ko) | 2006-02-20 |
Family
ID=35578306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030077256A KR100552634B1 (ko) | 2002-11-04 | 2003-11-03 | 돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100552634B1 (ko) |
CN (1) | CN1705743B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100769291B1 (ko) * | 2006-02-13 | 2007-10-24 | 조아제약주식회사 | 유선 특이적 인간 에리트로포이에틴 발현 벡터, 이를이용한 형질전환 동물 및 이를 이용한 인간에리트로포이에틴의 생산 방법 |
CN101012460B (zh) * | 2006-12-12 | 2010-05-19 | 浙江大学 | 猪生产性状相关基因cacna2d1的序列及其用途 |
EP2176414A4 (en) * | 2007-08-08 | 2011-01-26 | Cho A Pharm Co Ltd | EXPRESSION VECTOR FOR BREAST-DRY SPECIFIC HUMAN ERYTHROPOIETIN, TRANSGENIC ANIMAL AND METHOD FOR THE PRODUCTION OF HUMAN ERYTHROPOIETIN USING THEREOF |
JP5507555B2 (ja) | 2008-06-30 | 2014-05-28 | チョ−エー・ファーム・カンパニー・リミテッド | 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途 |
CA2729623C (en) | 2008-06-30 | 2014-06-10 | Cho-A Pharm Co., Ltd. | A gene of porcine beta-casein, a promoter of the same and the use thereof |
CN101886075B (zh) * | 2010-07-02 | 2011-12-21 | 东北农业大学 | 猪rosa26启动子及其应用 |
CN101979547B (zh) * | 2010-09-02 | 2012-04-25 | 华中农业大学 | 一种适用于猪骨骼肌基因表达的启动子的分离克隆及核心区域的鉴定 |
CN102127545A (zh) * | 2010-11-24 | 2011-07-20 | 山东农业大学 | 一种骨骼肌特异性ckm启动子及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824543A (en) * | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
US6339183B1 (en) * | 1995-06-05 | 2002-01-15 | New York University | Transgenic mammals expressing heterologous DNA in urothelium and isolation of biologically active molecules from urine |
-
2003
- 2003-11-03 KR KR1020030077256A patent/KR100552634B1/ko active IP Right Grant
- 2003-11-04 CN CN200380101482XA patent/CN1705743B/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1705743A (zh) | 2005-12-07 |
KR20040039168A (ko) | 2004-05-10 |
CN1705743B (zh) | 2011-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lakso et al. | Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. | |
EP1071471B1 (en) | Methods and vectors for making transgenic rodents which ubiquitously express a heterologous gene | |
Kues et al. | Epigenetic silencing and tissue independent expression of a novel tetracycline inducible system in double‐transgenic pigs | |
JP2004515212A (ja) | 改変es細胞およびes細胞特異的遺伝子 | |
JP5507555B2 (ja) | 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途 | |
CA2114112A1 (en) | Transgenic protein production | |
US5681735A (en) | Transcription control element for increasing gene expression in myoblasts | |
KR100552634B1 (ko) | 돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 | |
JPH04505710A (ja) | ポリペプチドの改良された発現 | |
WO2001030992A2 (en) | α1-3 GALACTOSYLTRANSFERASE GENE AND PROMOTER | |
CN107287236B (zh) | 一种人急性胰腺炎小鼠模型的构建方法 | |
EP0453458B1 (en) | Process for producing a transgenic non-human animal by introduction of exogenous dna in somatic and germ animal cells | |
US6252130B1 (en) | Production of somatic mosaicism in mammals using a recombinatorial substrate | |
CN106521638A (zh) | 一种基因突变大鼠资源库及其制备方法 | |
KR20070081531A (ko) | 유선 특이적 인간 에리트로포이에틴 발현 벡터, 이를이용한 형질전환 동물 및 이를 이용한 인간에리트로포이에틴의 생산 방법 | |
CN101855352A (zh) | 乳腺特异性人促红细胞生成素表达载体、转基因动物和利用其产生人促红细胞生成素的方法 | |
CN106978416A (zh) | 一种基因定位整合表达系统及其应用 | |
ES2286484T3 (es) | Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones. | |
EP1558735B1 (en) | Porcine uroplakin ii promoter and the production method of useful proteins using said promoter | |
CN109295000A (zh) | 一种多能干细胞形成必需蛋白crept的在诱导多能干细胞中的应用 | |
CN109295090B (zh) | 一种细胞周期调控蛋白crept在动物胚胎干细胞多能性维持中的应用 | |
US6977157B2 (en) | Clock gene promoter | |
CN115322993B (zh) | 一种用于猪基因组定点整合外源基因的安全位点及用其构建猪育种群方法 | |
US20120202286A1 (en) | rbLIF PROTEIN FOR USE IN EMBRYONIC STEM CELL CULTURES | |
CN116868959A (zh) | Rag2基因编辑免疫缺陷模型犬的建立方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130108 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160108 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170109 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180108 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190108 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20200108 Year of fee payment: 15 |